181 related articles for article (PubMed ID: 25939760)
1. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
3. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
4. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
Lee J; Jiffar T; Kupferman ME
PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
6. Bim protein degradation contributes to cisplatin resistance.
Wang J; Zhou JY; Wu GS
J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
[TBL] [Abstract][Full Text] [Related]
7. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
8. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.
Romano G; Acunzo M; Garofalo M; Di Leva G; Cascione L; Zanca C; Bolon B; Condorelli G; Croce CM
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16570-5. PubMed ID: 23012423
[TBL] [Abstract][Full Text] [Related]
9. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
10. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
[TBL] [Abstract][Full Text] [Related]
11. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
[TBL] [Abstract][Full Text] [Related]
12. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
13. Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.
Kong LR; Tan TZ; Ong WR; Bi C; Huynh H; Lee SC; Chng WJ; Eichhorn PJA; Goh BC
Mol Oncol; 2017 Aug; 11(8):965-980. PubMed ID: 28397399
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
15. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
16. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
18. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
19. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma.
Aoki K; Ogawa T; Ito Y; Nakashima S
Oncol Rep; 2004 Feb; 11(2):375-9. PubMed ID: 14719071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
